NeuBase Therapeutics to Present at the BTIG Virtual Biotechnology Conference on Tuesday, August 11th

Rhea-AI Summary

NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich Stephan will participate in the BTIG Virtual Biotechnology Conference 2020 on August 11 at 9:30 a.m. ET. This conference aims to highlight advancements in biotechnology, and NeuBase is at the forefront with its innovative PATrOL™ platform for developing antisense oligonucleotide therapies targeting genetic diseases. This session will be accessible via a webcast.

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the BTIG Virtual Biotechnology Conference 2020, being held on August 10 – 11.

BTIG Virtual Biotechnology Conference 2020:
Date:	Tuesday, August 11th
Time:	9:30 a.m. ET
Location:	Webcast Link - or at the company’s website (click here)

About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL™ technology, NeuBase aims to first tackle rare, genetic diseases.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366

 

FAQ

When is NeuBase participating in the BTIG Virtual Biotechnology Conference 2020?

NeuBase will participate in the BTIG Virtual Biotechnology Conference 2020 on August 11 at 9:30 a.m. ET.

Who is the CEO of NeuBase Therapeutics?

Dietrich Stephan is the Chief Executive Officer of NeuBase Therapeutics.

What is the focus of NeuBase's PATrOL™ platform?

NeuBase's PATrOL™ platform focuses on developing antisense oligonucleotide therapies for genetic diseases.

How can I access the BTIG Virtual Biotechnology Conference webcast?

The webcast for the BTIG Virtual Biotechnology Conference can be accessed through the NeuBase website or the provided webcast link.

What is the significance of the BTIG Virtual Biotechnology Conference for NeuBase?

The BTIG Virtual Biotechnology Conference is significant for NeuBase as it showcases the company's advancements in biotechnology and its innovative therapies.